title: Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
authors.affiliation: Department of Haematology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Garciaz
authors.affiliation: Department of Haematology, APHP, Hôpital Saint-Louis, Paris, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Harel
authors.affiliation: Department of Haematology, APHP, Hôpital Saint-Louis, Paris, France.
authors.forename: Sandy
authors.initials: S
authors.lastname: Amorim
authors.affiliation: Department of Haematology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Réda
authors.initials: R
authors.lastname: Bouabdallah
authors.affiliation: Department of Haematology, APHP, Hôpital Saint-Louis, Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.affiliation: Department of Haematology, APHP, Hôpital Saint-Louis, Paris, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001761:Bleomycin / Q000494:pharmacology / Q000627:therapeutic use; D003606:Dacarbazine / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab / Q000494:pharmacology / Q000627:therapeutic use*; D014747:Vinblastine / Q000494:pharmacology / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D001761:Bleomycin; D000069283:Rituximab; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin
keywords: Nodular lymphocyte predominant Hodgkin lymphoma; Rituximab